Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers

Reuters

Nov 15

Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers

Overview

Precipio Q3 2025 revenue grows 30% YoY to $6.8 mln
Adjusted EBITDA turns positive in Q3 2025, improving by over $500K from Q2
Company generates $285K cash from operations in Q3 2025

Outlook

Company anticipates gross margins to increase towards 50%

Result Drivers

PATHOLOGY SERVICES GROWTH - Revenue increased 20% due to new customer accounts in the pipeline
PRODUCT DIVISION EXPANSION - Revenue rose 16% from existing customers and new panel orders
OPERATIONAL EFFICIENCIES - Positive EBITDA and cash generation attributed to operational efficiencies and financial discipline

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue		$6.80 mln

Press Release: ID:nGNX4zwyxv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2583891682"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583891682\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583891682?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-15 05:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583891682","market":"fut","top_or_hot":-1,"title":"Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers </title></head><body><p><span>Overview</span></p><ul><li><p>Precipio Q3 2025 revenue grows 30% YoY to $6.8 mln</p></li><li><p>Adjusted EBITDA turns positive in Q3 2025, improving by over $500K from Q2</p></li><li><p>Company generates $285K cash from operations in Q3 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates gross margins to increase towards 50%</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PATHOLOGY SERVICES GROWTH - Revenue increased 20% due to new customer accounts in the pipeline</p></li><li><p>PRODUCT DIVISION EXPANSION - Revenue rose 16% from existing customers and new panel orders</p></li><li><p>OPERATIONAL EFFICIENCIES - Positive EBITDA and cash generation attributed to operational efficiencies and financial discipline</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$6.80 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX4zwyxv</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpecialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-15 05:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers </title></head><body><p><span>Overview</span></p><ul><li><p>Precipio Q3 2025 revenue grows 30% YoY to $6.8 mln</p></li><li><p>Adjusted EBITDA turns positive in Q3 2025, improving by over $500K from Q2</p></li><li><p>Company generates $285K cash from operations in Q3 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates gross margins to increase towards 50%</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PATHOLOGY SERVICES GROWTH - Revenue increased 20% due to new customer accounts in the pipeline</p></li><li><p>PRODUCT DIVISION EXPANSION - Revenue rose 16% from existing customers and new panel orders</p></li><li><p>OPERATIONAL EFFICIENCIES - Positive EBITDA and cash generation attributed to operational efficiencies and financial discipline</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$6.80 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX4zwyxv</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ154:1","article_id":"2583891682","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583891682","pubTimestamp":1763156395,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customersOverviewPrecipio Q3 2025 revenue grows 30% YoY to $6.8 mlnAdjusted EBITDA turns positive in Q3 2025, improving by","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","PRPO":"Precipio, Inc."},"translate_title":"专业癌症诊断公司Precipio第三季度收入在新客户的推动下增长30%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRPO":0.9},"content_text":"Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers OverviewPrecipio Q3 2025 revenue grows 30% YoY to $6.8 mlnAdjusted EBITDA turns positive in Q3 2025, improving by over $500K from Q2Company generates $285K cash from operations in Q3 2025OutlookCompany anticipates gross margins to increase towards 50%Result DriversPATHOLOGY SERVICES GROWTH - Revenue increased 20% due to new customer accounts in the pipelinePRODUCT DIVISION EXPANSION - Revenue rose 16% from existing customers and new panel ordersOPERATIONAL EFFICIENCIES - Positive EBITDA and cash generation attributed to operational efficiencies and financial disciplineKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Revenue$6.80 mlnPress Release: ID:nGNX4zwyxvFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}